Recent Updates
Recently added Catalysts
MNPR Positive Sentiment

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Tuesday, March 28, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Monopar Therapeutics Inc. will be presenting at the Jefferies Radiopharma Innovation Summit, with CEO Chandler Robinson scheduled to speak. The event is set to take place in New York City and emphasizes Monopar's commitment to developing therapeutics aimed at improving the lives of cancer patients. The company has a promising pipeline, which includes treatments for various cancer types.
Price reaction · baseline $14.9 (2023-03-27 close) · hit after-hours · clean, no other MNPR news in the window
day 0 close
-51.3%
day 1
-50.3%
day 3
-53.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Monopar's CEO will present at a notable industry event.
  • The company is focused on innovative therapeutics for cancer patients.
  • Monopar has a diverse pipeline of potential cancer treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+140%
120-day peak, hindsight
Typical move
5.5%
average across 4 past catalysts
Cash runway
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177Lu
Phase 1 · Solid Tumor, Adult

Full Press Release Details

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week.
Presentation Details:
Time: 1:00 – 1:30 pm
Location: Jefferies Conference Center, NYC, New York
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.
Monopar Therapeutics Inc.
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

Frequently Asked Questions

What is Monopar Therapeutics focused on?

Monopar Therapeutics specializes in developing therapeutics to extend life and improve quality of life for cancer patients.

Who will present at the Jefferies Summit?

Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present.

When is the presentation scheduled?

The presentation is set for March 28, 2023, from 1:00 to 1:30 pm.

Where will the presentation take place?

It will be held at Jefferies Conference Center in NYC, New York.

What is Monopar's key product in development?

Monopar's key products include camsirubicin, MNPR-101, and MNPR-202 for cancer treatments.

ShareAdd on Google
Tags: MNPR Viatris Investor Conferences Healthcare Monopar Jefferies Summit cancer therapeutics biopharmaceutical
Last updated: Mar 28, 2023

Biotech snapshot

Cash runway
$105M liquidity · $1M/mo burn
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177LuPhase 1
Solid Tumor, Adult →

Catalyst track record

+140%
best trade around MNPR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for MNPR.

See every catalyst's timing & PoA →